ATP4B
ENSG00000186009
Target class
Transporter
Chromosome
13
Approved drugs
10
Clinical candidates (approved and in development)
13
- Approved drugs
- 10
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- No
- Other names
- ATP6B
- Target name
- ATP4B
- Gene name
- ATPase H+/K+ transporting subunit beta
- Gene symbol
- ATP4B
- Protein name
- Potassium-transporting ATPase subunit beta (Gastric H(+)/K(+) ATPase subunit beta) (Proton pump beta chain)
- Gene biotype
- Protein coding
- Gene family
- ATPase H+/K+ transporting
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 1
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 1,162.26
- Tissue specificity (Gini)
- 0.979
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:496
- Reactome pathways
- R-HSA-936837
- Protein interaction confidence
- 0.843769
- Protein interaction partners
- 13
- End position
- 113658198
- Start position
- 113648804
- Chromosome
- 13
- Strand
- Reverse
- Apical cell membrane
- Single-pass type II membrane protein . Cell membrane
- Single-pass type II membrane protein . Note=Localized in the apical canalicular membrane of parietal cells. .
- Plasma membrane
- Tissue specificity (tau)
- 0.999884
- Expression inequality (Gini)
- 0.978648
Expression in transcripts per million
- Stomach
- 1,162.26
- Thyroid
- 0.78
- Spleen
- 0.76
- Kidney - Medulla
- 0.57
- Brain - Hypothalamus
- 0.35
Expression in transcripts per million
- Stomach1,162.26
- Thyroid0.78
- Spleen0.76
- Kidney - Medulla0.57
- Brain - Hypothalamus0.35
- Kidney - Cortex0.35
- Cells - EBV-transformed lymphocytes0.3
- Fallopian Tube0.28
- Testis0.28
- Pituitary0.27
- Cervix - Ectocervix0.22
- Cervix - Endocervix0.22
- Brain - Hippocampus0.22
- Uterus0.15
- Small Intestine - Terminal Ileum0.13
- Brain - Amygdala0.12
- Prostate0.12
- Brain - Cerebellum0.11
- Ovary0.11
- Esophagus - Mucosa0.1
- Brain - Spinal cord (cervical c-1)0.1
- Colon - Transverse0.09
- Lung0.09
- Vagina0.08
- Brain - Caudate (basal ganglia)0.08
And 29 more, listed on the interactive page.
Cellular components
- GO:0005886
- GO:0005515
- GO:0008900
Related records
Trials (1,435)
- "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
- +AGIL Barcelona: Integrated Care for Community-Dwelling Frail Older Adults
- 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication
- 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection
- 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
- 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
- 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication
- 15-day Sequential Therapy for Helicobacter Pylori Infection in Korea
- 24-h Energy Expenditure and Anti-obesity Medication
- 3D Tissue Engineered Bone Equivalent for Treatment of Traumatic Bone Defects
- 5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection
- 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication
- 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori
- A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
- A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet
- A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers
- A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)
- A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults
Drugs (17)
- Abeprazan Potassium-transporting ATPase inhibitor
- Dexlansoprazole Potassium-transporting ATPase inhibitor
- Esomeprazole Potassium-transporting ATPase inhibitor
- Esomeprazole magnesium Potassium-transporting ATPase inhibitor
- Esomeprazole sodium Potassium-transporting ATPase inhibitor
- Esomeprazole strontium Potassium-transporting ATPase inhibitor
- Ilaprazole Potassium-transporting ATPase inhibitor
- Lansoprazole Potassium-transporting ATPase inhibitor
- Omeprazole Potassium-transporting ATPase inhibitor
- Omeprazole magnesium Potassium-transporting ATPase inhibitor
- Pantoprazole Potassium-transporting ATPase inhibitor
- Pantoprazole sodium Potassium-transporting ATPase inhibitor
- Rabeprazole Potassium-transporting ATPase inhibitor
- Rabeprazole sodium Potassium-transporting ATPase inhibitor
- Tegoprazan Potassium-transporting ATPase blocker
- Vonoprazan Potassium-transporting ATPase inhibitor
- Vonoprazan fumarate Potassium-transporting ATPase inhibitor